Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
NCT02702414
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
156
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL:
Pembrolizumab
Sponsor
Merck Sharp & Dohme LLC